EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors



Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors



Journal of Hepatocellular Carcinoma 2(): 3-9



Hepatocellular carcinoma (HCC) is a common cancer worldwide as well as in Egypt with hepatitis C and B, alcohol and aflatoxins being the commonest risk factors. The objective of this study was to assess the prognostic factors affecting overall survival (OS) of untreated HCC in Egypt. This retrospective study was conducted at Tanta Cancer Center, Egypt where 288 HCC cases who received no specific therapy and were followed-up until death were identified. The impact of possible prognostic factors on OS was assessed using the log-rank test (univariate analyses) and Cox regression method (multivariate analysis). The median OS of untreated HCC was 2.3 months (95% confidence interval: 1.9-2.6). The 1, 3, 6, 12, 24 months OS rates were 84%, 42%, 21%, 9%, and 3%, respectively. All cases had died by 46 months. Male sex, advanced Child-Pugh class, the clinical presentation of ascites, cough, fatigue, and the presence of metastases were associated with poor survival (P<0.05 for all). In multivariate analysis; cough, presence of ascites, and Child-Pugh class were independent predictors of poor survival. OS in untreated HCC in Egypt is very short. Many factors interact to produce this dismal survival.

(PDF emailed within 0-6 h: $19.90)

Accession: 059203833

Download citation: RISBibTeXText

PMID: 27508189

DOI: 10.2147/JHC.S73828



Related references

Prognostic factors for survival of small less than or equal to 5 cm untreated hepatocellular carcinoma in the west. Journal of Hepatology 13(SUPPL 2): S98, 1991

Prognostic factors for survival of small equal to or less than 5 cm untreated hepatocellular carcinoma in the west. Hepatology 14(4 PART 2): 171A, 1991

Natural history and prognostic factors of primary hepatocellular carcinoma: study of 70 untreated patients. Korean Journal of Internal Medicine 4(2): 136-141, 1989

Prognostic factors and their relative time value in patients with liver cirrhosis and untreated hepatocellular carcinoma hcc. Journal of Hepatology 13(SUPPL 2): S3, 1991

Natural history of small untreated hepatocellular carcinoma in cirrhosis a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 16(1): 132-137, 1992

Surgical outcome and prognostic factors of metastatic spine hepatocellular carcinoma. World Neurosurgery: -, 2018

Percutaneous ethanol injection for hepatocellular carcinoma 2-year outcome and prognostic factors. 2012

Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Clinical Imaging 33(1): 79-0, 2009

Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. European Journal of Radiology 67(2): 336-347, 2007

Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver International 32(9): 1434-1442, 2013

Prognostic factors and outcome in patients with intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 31(8): 612-616, 2011

Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Annals of Surgical Oncology 14(10): 2817-2823, 2007

Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. European Journal of Surgical Oncology 30(4): 414-420, 2004

Liver resection in hepatocellular carcinoma: Outcome, long-term results, and prognostic factors. Journal of Gastrointestinal Surgery 9(4): 573-573, 2005

Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. Journal of Hepatology 62(5): 1112-1121, 2016